The role of bevacizumab in the treatment of glioblastoma

Journal of Neuro-oncology
Roberto Jose DiazRicardo J Komotar

Abstract

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken. We found that the available literature supports the use of bevacizumab for prolonging PFS and OS in the recurrent setting either alone or in combination with a cytotoxic agent (P < 0.05), but does not support its use in the primary setting (P > 0.05). The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. There is no additional benefit reported to date in health-related quality of life with the use of bevacizumab, although it may reduce steroid requirements. On average there is one side-effect event per patient and 74% of these events are grade 3 toxicity or higher. Further studies inves...Continue Reading

References

Jul 29, 2004·Neuro-oncology·Siew-Ju SeeMorris D Groves
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 29, 2008·Journal of Neuro-oncology·Camilo E FadulJ Marc Pipas
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Jan 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J C VerhoeffD J Richel
Aug 19, 2010·Neuro-oncology·Sith SathornsumeteeDavid A Reardon
Nov 3, 2010·International Journal of Radiation Oncology, Biology, Physics·James J VredenburghHenry S Friedman
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert LaiTimothy Cloughesy
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J VredenburghHenry S Friedman
Jul 28, 2011·Cancer·Annick DesjardinsJames J Vredenburgh
Oct 12, 2011·Journal of Neuro-oncology·David A ReardonHenry S Friedman
Nov 1, 2011·Journal of Neurosurgery·Ashwatha NarayanaMichael L Gruber
Feb 9, 2012·Chemotherapy Research and Practice·Seema NagpalLawrence Recht
Feb 5, 2013·Epidemiology·Jiajie ZangJia He
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark R GilbertMinesh P Mehta
Feb 19, 2014·Journal of Neuro-oncology·Johanna QuickChristian Senft
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Jun 21, 2014·Future Oncology·Alba A BrandesAntoine F Carpentier
Feb 7, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael WellerUNKNOWN DIRECTOR Study Group
Apr 23, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Linda DirvenUNKNOWN Dutch Neuro-Oncology Group (LWNO)
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J B TaphoornOlivier L Chinot
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulrich HerrlingerMartin Glas
Apr 8, 2016·Expert Opinion on Pharmacotherapy·Katharina SeystahlMichael Weller

❮ Previous
Next ❯

Citations

Nov 22, 2017·International Journal of Molecular Sciences·Michael C BurgerJoachim P Steinbach
May 14, 2018·Applied Microbiology and Biotechnology·Xuyao ZhangDianwen Ju
Apr 17, 2018·Neuro-oncology·Viveka Nand YadavPedro R Löwenstein
Aug 29, 2018·International Journal of Molecular Sciences·Virgil E J C SchijnsApostolos Stathopoulos
Jun 6, 2018·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Gagandeep ChoudharyJonathan McConathy
Apr 25, 2019·CNS Neuroscience & Therapeutics·En-Ming KangXiang Zhang
Oct 14, 2017·The Journal of Pharmacology and Experimental Therapeutics·Maria Grazia AtzoriGrazia Graziani
Jan 26, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Neja ŠamecIvana Jovčevska
Feb 9, 2020·International Journal of Molecular Sciences·Ilanah J PruisSophie E M Veldhuijzen van Zanten
Jun 2, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Galia TiramRonit Satchi-Fainaro
May 14, 2020·Expert Opinion on Investigational Drugs·Maria B Garcia-FabianiMaria G Castro
Jul 10, 2020·Human Vaccines & Immunotherapeutics·Tianrui YangWenbin Ma
May 12, 2018·International Journal of Molecular Medicine·Igor BryukhovetskiyYuri Khotimchenko
Sep 5, 2020·The Journal of International Medical Research·Can ChenYanling Zhang
Nov 30, 2019·Scientific Reports·Mustafa S AschaJill S Barnholtz-Sloan
Jul 29, 2020·Cancer Reports·Stephen LoweAdriana Olar
Oct 3, 2018·Frontiers in Pharmacology·Edouard Alphandéry
Oct 31, 2018·Frontiers in Oncology·Kewal K Jain
Jan 20, 2018·Journal of Neuro-oncology·Daniel DubinskiChristian Senft
Sep 14, 2018·International Journal of Molecular Sciences·Ángelo TorresClaudia Quezada
Sep 10, 2020·Journal of Personalized Medicine·Hassan Rahimi KoshkakiAurelia Rughetti
Oct 11, 2020·International Journal of Molecular Sciences·Maria PeleliAndreas Papapetropoulos
Oct 20, 2020·Frontiers in Cell and Developmental Biology·Ya XuHua-Tao Wu
Oct 14, 2020·Cell Biology International·S Daisy PrecillaAnitha Thirugnanasambandhar Sivasubramanian
Dec 20, 2020·Pharmaceuticals·Yusuke FunakoshiMasahiro Mizoguchi
Dec 5, 2020·Continuum : Lifelong Learning in Neurology·Deborah A Forst

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.